Business
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 5, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a
About this update from Pavmed Inc.
[{"type":"text","content":"Conference Call and Webcast at 8:30AM Eastern Time\nNEW YORK, May 5, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, May 17, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's first-quarter 2023 financial results.\n\n \n \n \n \n \n \n\n \nThe webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-866-652-5200 and international listeners should dial 1-412-317-6060. All listeners should provide the operator with the conference call name \"PAVmed Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.\nAbout PAVmedPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.\nFor more and for more information about PAVmed, please visit pavmed.com.\nFo...